Improving adherence and clinical outcomes through an HIV pharmacist's interventions

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 22, Issue 10, 2010, Pages 1189-1194

  Ma, Angela ^a   Chen, David M ^a   Chau, Fern M ^a   Saberi, Parya ^a,b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adherence; clinical; HIV; intervention; pharmacist; regimen complexity

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DRUG DOSE REGIMEN; ELECTRONIC PRESCRIBING; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACIST; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT INDICATION; VIRUS LOAD;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACEUTICAL SERVICES; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 77956941064     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540121003668102     Document Type: Article

References (16)

1. Carr, R.L., & Gramling, L.F. (2004). Stigma: A health barrier for women with HIV/AIDS. Journal of the Association of Nurses in AIDS Care, 15, 30-39.
2. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. (2008). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Retrieved from http://www.aidsinfo.nih.gov/Content-Files/AdultandAdolescentGL.pdf.
3. Gallant, J.E., DeJesus, E., Arribas, J.R., Pozniak, A.L., Gazzard, B., Campo, R.E., . . . study 934 Group. (2006). Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine, 354, 251-260.
4. Gatell, J., Salmon-Ceron, D., Lazzarin, A., Van Wijngaerden, E., Antunes, F., Leen, C., . . . SWAN Study Group. (2007). Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN Study (AI424-097) 48-week results. Clinical Infectious Diseases, 44, 1484-1492.
5. Grossberg, R., Zhang, Y., & Gross, R. (2004). A time-toprescription- refill measure of antiretroviral adherence predicted changes in viral load in HIV. Journal of Clinical Epidemiology, 57, 1107-1110.
6. Halkitis, P.N., Shrem, M.T., Zade, D.D., & Wilton, L. (2005). The physical, emotional and interpersonal impact of HAART: Exploring the realities of HIV seropositive individuals on combination therapy. Journal of Health Psychology, 10, 345-358.
7. Horberg, M.A., Hurley, L.B., Silverberg, M.J., Kinsman, C.J., & Quesenberry, C.P. (2007). Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 44(5), 531-539.
8. Ingersol, K.S., & Cohen, J. (2008). The Impact of medication regimen factors on adherence to chronic treatment: A review of literature. Journal of Behavioral Medicine, 31, 213-224.
9. Kitahata, M.M., Reed, S.D., Dillingham, P.W., Van Rompaey, S.E., Young, A.A., Harrington, R.D., Holmes, K.K. (2004). Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. International Journal of STD & AIDS, 15, 803-810.
10. Lee, J.K., Grace, K.A., & Taylor, A.J. (2006). Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. Journal of the American Medical Association, 296, 2563-2571.
11. March, K., Mak, M., & Louie, S.G. (2007). Effects of pharmacists interventions on patient outcomes in an HIVprimary care clinic. American Journal of Health-System Pharmacy, 64, 2547-2579.
12. Marcus, E.N. (2006). The silent epidemic the health effects of illiteracy. New England Journal of Medicine, 355, 339-341.
13. Molina, J.M., Podsadecki, T.J., Johnson, M.A., Wilkin, A., Domingo, P., Myers, R., . . . Hanna, G.J. (2007). A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Research and Human Retroviruses, 23, 1505-1514.
14. Paterson, D.L., Swindells, S., Mohr, J., Brester, M., Vergis, E.N., Squier, C., . . . Singh, N. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIVinfection. Annals of Internal Medicine, 133, 21-30.
15. Rathbun, R.C., Farmer, K.C., Stephens, J.R., & Lockhart, S.M. (2005). Impact of an adherence clinic on behavioral outcomes and virologic response in the treatment of HIVinfection: A prospective, randomized controlled pilot study. Clinical Therapeutics, 27(2), 199-209.
16. Saberi, P., Caswell, N., Amodio-Groton, M., & Alpert, P. (2008). Pharmacy-refill measure of adherence to efavirenz can predict maintenance of HIVviral suppression. AIDS Care, 20(6), 741-745.